Phase 3, Open-Label, Randomized Study of Gilteritinib and Azacitidine Vs Azacitidine for Newly Diagnosed <i>FLT3</i>-Mutated Acute Myeloid Leukemia in Patients Ineligible for Intensive Induction Chemotherapy
Eunice S. Wang(Roswell Park Comprehensive Cancer Center), Ramón V. Tiu(Eli Lilly (United States)), Wen‐Chien Chou(National Taiwan University), Kamel Laribi(Centre Hospitalier du Mans), Jordi Esteve(Consorci Institut D'Investigacions Biomediques August Pi I Sunyer), Jessica K. Altman(Northwestern University), Mark D. Minden(University Health Network), Elizabeth Rich(Astellas Pharma (United States)), Nisha Philipose(Astellas Pharma (United States)), Michael Heuser(Martin Luther University Halle-Wittenberg), Anne-Marie Watson(Liverpool Hospital), Ruishan Wu(Astellas Pharma (United States)), Elżbieta Patkowska(Institute for Transfusion Medicine), Jason E. Hill(Essen BioScience (United States)), Violaine Havelange(Cliniques Universitaires Saint-Luc), Stanley C. Gill(Nivalis Therapeutics (United States)), Shufang Liu(Qingdao National Laboratory for Marine Science and Technology), Je‐Hwan Lee(Ulsan College), Tomoki Naoe(National Hospital Organization), Pau Montesinos(Instituto de Salud Carlos III)
Cited by 20
Related Papers
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
|Blood|2016|5.9k
Genomic Classification and Prognosis in Acute Myeloid Leukemia
|New England Journal of Medicine|2016|4.4k
Durable Remissions with Ivosidenib in <i>IDH1</i> -Mutated Relapsed or Refractory AML
|New England Journal of Medicine|2018|1.4k